An intensive course in the Lee Silverman Voice Treatment, known as LSVT Loud, may be the best strategy to help…
Articles by Margarida Maia, PhD
Once-daily treatment with IRX4204, an oral small molecule being developed by Io Therapeutics, showed a potential to safely…
The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being…
Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may…
People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such…
Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease —…
People with Parkinson’s disease who don’t always take Nourianz (istradefylline) as prescribed are more likely to have fewer…
Synthetic biology company Bit.bio introduced ioAstrocytes, a stem cell-derived version of astrocytes, cells that are known to play a…
A Phase 2 clinical study of AB-1005 (AAV2-GDNF), an experimental gene therapy AskBio is developing for Parkinson’s disease,…
Coya Therapeutics is building upon its collaboration with the Houston Methodist Research Institute, in Texas, to advance research into…